Systemic Immunotherapy of Non–Muscle Invasive Mouse Bladder Cancer with Avelumab, an Anti–PD-L1 Immune Checkpoint Inhibitor

類似資料

• Systemic immunotherapy of superficial mouse bladder cancer with Avelumab (MSB0010718C), an anti-PD-L1 immune checkpoint inhibitor
  著者:: Vandeveer, Amanda, 等
  出版事項: (2015)
• Enhanced antitumor effects by combining an IL-12/anti-DNA fusion protein with avelumab, an anti-PD-L1 antibody
  著者:: Fallon, Jonathan K., 等
  出版事項: (2017)
• Anti-tumor effects of anti-PD-L1 therapy in an orthotopic bladder tumor model
  著者:: Lyon, Amanda, 等
  出版事項: (2014)
• Perioperative immunotherapy for muscle-invasive bladder cancer
  著者:: Kim, In-Ho, 等
  出版事項: (2020)
• ADCC employing an NK cell line (haNK) expressing the high affinity CD16 allele with avelumab, an anti-PD-L1 antibody
  著者:: Jochems, Caroline, 等
  出版事項: (2017)